B. Antmen - Academia.edu (original) (raw)
Uploads
Papers by B. Antmen
20th Congress of European-Hematology-Association -- JUN 11-14, 2015 -- Vienna, AUSTRIAWOS: 000361... more 20th Congress of European-Hematology-Association -- JUN 11-14, 2015 -- Vienna, AUSTRIAWOS: 000361204904224
Therapeutic Advances in Hematology
Haemophilia is an X-linked lifelong congenital bleeding disorder that is caused by insufficient l... more Haemophilia is an X-linked lifelong congenital bleeding disorder that is caused by insufficient levels of factor VIII (FVIII; haemophilia A) or factor IX (FIX; haemophilia B) and characterized by spontaneous and trauma-related bleeding episodes. The cornerstone of the treatment, factor replacement, constitutes several difficulties, including frequent injections due to the short half-life of recombinant factors, intravenous administration and the risk of inhibitor development. While extended half-life factors and subcutaneous novel molecules enhanced the quality of life, initial successes with gene therapy offer a significant hope for cure. Although adeno-associated viral (AAV)-based gene therapy is one of the most emerging approaches for treatment of haemophilia, there are still challenges in vector immunogenicity, potency and efficacy, genotoxicity and persistence. As the approval for the first gene therapy product is coming closer, eligibility criteria for patient selection, multi...
Purpose: Haemophilia causes musculoskeletal problems over many years secondary to recurrent hemar... more Purpose: Haemophilia causes musculoskeletal problems over many years secondary to recurrent hemarthrosis. In this study, the effects of water exercises on the musculoskeletal system of severe haemophilia A patients with muscle and joint problems were investigated. Material and Methods: Eleven severe haemophilia A patients on prophylaxis treatment participated in the study and following a regular exercise protocol. Results: Subjects displayed statistically significant increases in mid-thigh, upper thigh and calf circumference for right leg (42.0 ± 2.4, 43.0 ±2.1 ; 37.1 ±1.9, 39.0 ±1.8; 28.1 ± 1.4, 28.9 ±1.3 respectively) (mean ± SE) in mid-thigh and upper thigh for left leg (36.9 ± 1.5 , 38.9 ± 1.5 ; 41.2 ± 2.2 , 42.9 ± 2) (p<0.05). Compared to pre-exercise values, leg extensor and flexor strength as well as range of motion were increased significantly (96.6 ± 9º vs 104.5± 8º; before and after training for right knee, 98.5 ± 7.6 º vs 104 ± 7.9 º before and after training for left ...
41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation -- MAR 22-25, 20... more 41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation -- MAR 22-25, 2015 -- Istanbul, TURKEYWOS: 000351632902302European Soc Blood & Marrow Transplanta
42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation -- APR 03-06, 20... more 42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation -- APR 03-06, 2016 -- Valencia, SPAINWOS: 000373357600399…European Soc Blood & Marrow Transplanta
Oksuz, Ergun/0000-0002-5723-5965WOS: 000503167003144[No abstract available
Blood, 2005
Objective: Prothrombin complex concentrates (PCC), active prothrombin complex concentrates (APCC;... more Objective: Prothrombin complex concentrates (PCC), active prothrombin complex concentrates (APCC;FEIBA) or recombinant Factor VIIa (rFVIIa; Novoseven) are safely used for the treatment of hemorrhages in hemophiliac patients with inhibitors or during the interventions performed in these patients. A hemophilia-A patient with inhibitors in whom bilateral cataract operation and circumcision were successfully performed by rFVIIa administration was presented. Case: The 13 year old male patient had been diagnosed with severe Hemophilia-A by the detection of a FVIII level below 1% in the factor assay performed due to echhymoses in his body when he was 6 months old. The inhibitor level of the patient who developed bilateral cataract during the follow-up period was determined as 2.95 BU; however the cataract operation had to be delayed due to the absence of an adequate increase in his factor VIII level despite the 2000 U factor replacement administered in July 2002. The patient was readmitted...
Journal of Thrombosis and Haemostasis, 2017
20th Congress of European-Hematology-Association -- JUN 11-14, 2015 -- Vienna, AUSTRIAWOS: 000361... more 20th Congress of European-Hematology-Association -- JUN 11-14, 2015 -- Vienna, AUSTRIAWOS: 000361204904224
Therapeutic Advances in Hematology
Haemophilia is an X-linked lifelong congenital bleeding disorder that is caused by insufficient l... more Haemophilia is an X-linked lifelong congenital bleeding disorder that is caused by insufficient levels of factor VIII (FVIII; haemophilia A) or factor IX (FIX; haemophilia B) and characterized by spontaneous and trauma-related bleeding episodes. The cornerstone of the treatment, factor replacement, constitutes several difficulties, including frequent injections due to the short half-life of recombinant factors, intravenous administration and the risk of inhibitor development. While extended half-life factors and subcutaneous novel molecules enhanced the quality of life, initial successes with gene therapy offer a significant hope for cure. Although adeno-associated viral (AAV)-based gene therapy is one of the most emerging approaches for treatment of haemophilia, there are still challenges in vector immunogenicity, potency and efficacy, genotoxicity and persistence. As the approval for the first gene therapy product is coming closer, eligibility criteria for patient selection, multi...
Purpose: Haemophilia causes musculoskeletal problems over many years secondary to recurrent hemar... more Purpose: Haemophilia causes musculoskeletal problems over many years secondary to recurrent hemarthrosis. In this study, the effects of water exercises on the musculoskeletal system of severe haemophilia A patients with muscle and joint problems were investigated. Material and Methods: Eleven severe haemophilia A patients on prophylaxis treatment participated in the study and following a regular exercise protocol. Results: Subjects displayed statistically significant increases in mid-thigh, upper thigh and calf circumference for right leg (42.0 ± 2.4, 43.0 ±2.1 ; 37.1 ±1.9, 39.0 ±1.8; 28.1 ± 1.4, 28.9 ±1.3 respectively) (mean ± SE) in mid-thigh and upper thigh for left leg (36.9 ± 1.5 , 38.9 ± 1.5 ; 41.2 ± 2.2 , 42.9 ± 2) (p<0.05). Compared to pre-exercise values, leg extensor and flexor strength as well as range of motion were increased significantly (96.6 ± 9º vs 104.5± 8º; before and after training for right knee, 98.5 ± 7.6 º vs 104 ± 7.9 º before and after training for left ...
41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation -- MAR 22-25, 20... more 41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation -- MAR 22-25, 2015 -- Istanbul, TURKEYWOS: 000351632902302European Soc Blood & Marrow Transplanta
42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation -- APR 03-06, 20... more 42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation -- APR 03-06, 2016 -- Valencia, SPAINWOS: 000373357600399…European Soc Blood & Marrow Transplanta
Oksuz, Ergun/0000-0002-5723-5965WOS: 000503167003144[No abstract available
Blood, 2005
Objective: Prothrombin complex concentrates (PCC), active prothrombin complex concentrates (APCC;... more Objective: Prothrombin complex concentrates (PCC), active prothrombin complex concentrates (APCC;FEIBA) or recombinant Factor VIIa (rFVIIa; Novoseven) are safely used for the treatment of hemorrhages in hemophiliac patients with inhibitors or during the interventions performed in these patients. A hemophilia-A patient with inhibitors in whom bilateral cataract operation and circumcision were successfully performed by rFVIIa administration was presented. Case: The 13 year old male patient had been diagnosed with severe Hemophilia-A by the detection of a FVIII level below 1% in the factor assay performed due to echhymoses in his body when he was 6 months old. The inhibitor level of the patient who developed bilateral cataract during the follow-up period was determined as 2.95 BU; however the cataract operation had to be delayed due to the absence of an adequate increase in his factor VIII level despite the 2000 U factor replacement administered in July 2002. The patient was readmitted...
Journal of Thrombosis and Haemostasis, 2017